BN
|
HealthAI Desk•1 views

FDA Approves Eli Lilly's GLP-1 Pill, Boosting Oral Weight Loss Options

The FDA has approved Eli Lilly's oral GLP-1 drug, Foundayo, for weight loss, acquired from Chugai in 2018. With moderate efficacy at 12.4% average weight loss, it is less effective than injectables but offers pill convenience. Priced at $149 for cash payers and $25 with insurance, it competes with Novo Nordisk's Wegovy pill, which has higher efficacy. Analysts forecast $14.79 billion in sales by 2030. Lilly plans global expansion to over 40 countries, leveraging manufacturing investments for broad accessibility.

Ad slot
FDA Approves Eli Lilly's GLP-1 Pill, Boosting Oral Weight Loss Options

The U.S. Food and Drug Administration has approved Eli Lilly's oral GLP-1 drug, Foundayo, for chronic weight management, marking a significant expansion in the obesity treatment landscape and initiating direct competition with Novo Nordisk's recently launched Wegovy pill.

Approval and Launch Details

  • The FDA granted approval under a priority review program, with Lilly submitting the drug only months ago.
  • Foundayo will be available through LillyDirect starting Monday, with distribution to pharmacies and telehealth platforms to follow shortly.

Drug Efficacy and Background

  • Foundayo, based on orforglipron licensed from Chugai in 2018 for $50 million, showed an average weight loss of 12.4% in clinical trials.
  • Efficacy is lower than Lilly's injectable Zepbound (over 20% loss) and Novo's Wegovy pill (16.6% loss), but it offers convenience as a daily pill.
  • As a small molecule, Foundayo simplifies manufacturing and avoids cold-chain logistics, unlike peptide-based injectables.
Ad slot

Pricing and Patient Access

  • Cash price ranges from $149 to $349 per month depending on dose.
  • Insured patients can use a Lilly coupon for a $25 monthly cost.
  • Medicare beneficiaries will pay $50 monthly starting summer 2024, per agreements with the Trump administration.
  • The pill format targets patients hesitant about injections or seeking affordability.

Market Competition and Forecasts

  • Foundayo competes directly with Novo Nordisk's Wegovy pill, which recorded over 600,000 prescriptions in March.
  • Analysts project Foundayo sales to reach $14.79 billion by 2030, compared to $24.68 billion for Zepbound and $44.87 billion for Mounjaro.
  • Both Foundayo and Wegovy share a $149 starting price, making cost a critical factor for patients and clinicians.

Global Expansion and Manufacturing

  • Lilly anticipates regulatory approval in over 40 countries within the next year.
  • Since 2020, the company has invested over $55 billion in manufacturing to support global scale-up.
  • CEO Dave Ricks emphasizes Foundayo's scalability for worldwide supply without injectable constraints.

Future Outlook and Strategic Implications

  • Lilly's stock, down 14% this year, may recover based on Foundayo's launch performance and prescription trends.
  • Upcoming data for retatrutide, a potent obesity shot, could enhance Lilly's portfolio.
  • Ricks states the goal is to provide patient choices, whether through Foundayo or other Lilly products.
Ad slot